Background Observational studies including time-varying treatments are prone to confounding. We compared time-varying Cox regression analysis, propensity score (PS) methods, and marginal structural models (MSMs) in a study of antidepressant [selective serotonin reuptake inhibitors (SSRIs)] use and the risk of hip fracture. Methods A cohort of patients with a first prescription for antidepressants (SSRI or tricyclic antidepressants) was extracted from the Dutch Mondriaan and Spanish Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP) general practice databases for the period 2001-2009. The net (total) effect of SSRI versus no SSRI on the risk of hip fracture was estimated using time-varying Cox regression, stratification and covariate adjustment using the PS, and MSM. In MSM, censoring was accounted for by inverse probability of censoring weights. Results The crude hazard ratio (HR) of SSRI use versus no SSRI use on hip fracture was 1.75 (95%CI: 1.12, 2.72) in Mondriaan and 2.09 (1.89, 2.32) in BIFAP. After confounding adjustment using time-varying Cox regression, stratification, and covariate adjustment using the PS, HRs increased in Mondriaan [2.59 (1.63, 4.12), 2.64 (1.63, 4.25), and 2.82 (1.63, 4.25), respectively] and decreased in BIFAP [1.56 (1.40, 1.73), 1.54 (1.39, 1.71), and 1.61 (1.45, 1.78), respectively]. MSMs with stabilized weights yielded HR 2.15 (1.30, 3.55) in Mondriaan and 1.63 (1.28, 2.07) in BIFAP when accounting for censoring and 2. 13 (1.32, 3.45) in Mondriaan and 1.66 (1.30, 2.12) in BIFAP without accounting for censoring. Conclusions In this empirical study, differences between the different methods to control for time-dependent confounding were small. The observed differences in treatment effect estimates between the databases are likely attributable to different confounding information in the datasets, illustrating that adequate information on (time-varying) confounding is crucial to prevent bias.
INTRODUCTION
Antidepressants, notably selective serotonin reuptake inhibitors (SSRIs), have been associated with increased risk of femur or hip fracture. 1, 2 In observational studies, patients' exposure to SSRI medication may change over time; that is, physicians may stop SSRI therapy or switch to other classes of antidepressants because of adverse effects such as sexual dysfunction and drowsiness. Patients may not adhere to the prescribed drug regimen. 3 Furthermore, the severity of the depression, co-medication use (e.g., benzodiazepine), and the presence of other co-morbidities (e.g., anxiety) might change over time and may influence the use of antidepressants at later time points, hence, confounding the observed relationship between antidepressant use and hip fracture. On the other hand, antidepressant medication treatment may improve subsequent depression severity or co-medications such as benzodiazepine use. As a result, unbiased estimation of the (net) effect of SSRI use over time on the risk of hip fracture requires that the time-varying nature of both SSRI treatment and confounders (in particular, the potential for some confounders to simultaneously act as a mediator and confounder of the treatment effect, e.g., severity of depression and benzodiazepine use) is accounted for. 4, 5 Here, the effect of interest is the net (total) effect of SSRI use (defined as SSRI use during the current and previous periods) on hip fracture.
Cox proportional hazard models with time-varying coefficients are capable of addressing the time-varying nature of both treatment and covariates. 6, 7 However, when potential confounders are themselves affected by the previous SSRI use, the time-varying Cox model can no longer provide unbiased estimates of the treatment effect. 8, 9 This is because the time-dependent confounding factors are also intermediates on the causal path from treatment to outcome, and conditioning on such factors will artificially dilute (or 'adjust-away' part of) the treatment, SSRI use, effect. [8] [9] [10] [11] In addition, when such time-dependent confounders are common effects (i.e., colliders) of previous treatment and unmeasured factors that are also predictors of outcome (in this example, the risk of hip fracture), time-varying Cox models 8, 9 and propensity score (PS) methods that condition on timedependent confounders (colliders) induce a non-causal association between previous treatment and unmeasured risk factors, thereby introducing collider-stratification bias. 8, 9, 12 The potential associations between treatment (SSRI use), covariates, outcome (hip fracture), and the impact of adjustment methods are depicted using causal diagrams in the Supporting Information (Appendix 1).
In inverse probability of treatment weighting (IPTW) estimation of marginal structural models (MSMs), a weight is assigned to each observation that is proportional to the inverse of the probability of treatment received given time-dependent confounders and previous treatment. This method provides unbiased estimates of causal treatment effects under the following assumptions: (i) exchangeability, that is, no unmeasured confounding or informative censoring; (ii) positivity; that is, both treated and untreated subjects exist at each level of confounders; (iii) correct model specification; (iv) the intervention is well defined; that is, there are no unrepresented versions of treatment; and (v) no measurement error in exposure, covariates, and outcome. 8, 9, 13 Moreover, inverse probability of censoring weighting in MSMs enables investigators to control for bias because of informative censoring, that is, nonrandom or systematic loss to follow-up. 8, 9 Often ignored but important in comparing the different methods is the key difference between the methods under consideration: The parameters are typically not equal, even in the absence of (time-dependent) confounding. The MSM addresses a marginal hazard ratio (HR) while the Cox model and other PS methods estimate a conditional HR. [8] [9] [10] [11] [12] The conditional estimates from conventional Cox model and PS models are often different in the absence of a null treatment effect because of non-collapsibility. The estimate is conditional on all the covariates included in the outcome model and the summary of the covariates, the PS, in the conventional Cox and the PS methods, respectively.
Our primary objective was to assess the sensitivity of the estimated net (total) effect of SSRI use on the risk of hip fracture to different approaches of controlling timedependent confounding, including time-varying Cox model, PS methods, and MSMs using inverse probability of treatment and/or censoring weights. The second objective was to assess whether this sensitivity differed between two observational databases, with varying information on covariates.
METHODS

Data sources and study population
The Mondriaan databases include the Netherlands Primary Care Research Database and the Almere Health Care database.
14 The Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP) database, a computerized database of medical records of primary care, is a non-profit research department operated by the Spanish Medicines Agency (Agencia Española de Medicamentos y Productos Sanitarios).
14 The BIFAP database includes clinical and prescription data from around 3.1 million patients covering around 6.8% of the Spanish population. In both databases, the International Classification in Primary Care (ICPC) is used for coding diagnoses, and the Anatomical Therapeutic Chemical classification system for coding drugs. Further details of the Mondriaan and BIFAP databases can be found elsewhere. 14 The study population included a cohort of patients with a first prescription for antidepressants [SSRI or tricyclic antidepressants (TCAs)] extracted from both the Dutch Mondriaan and Spanish BIFAP general practice (GP) databases for the period from 1 January 2001 to 31 December 2009.
Exposure, outcome, and potential confounders
Only patients who received at least one prescription of antidepressants, either SSRIs or TCAs, were included in this study. For each patient, all prescriptions for SSRI or TCA were identified, and treatment episodes were constructed. A treatment episode was defined as a series of subsequent prescriptions, irrespective of changes in dosage regimen or switching between antidepressants (SSRI or TCA). The theoretical duration of each prescription was estimated based on the number of tablets prescribed and the prescribed dosage regimen (BIFAP). In Mondriaan, prescription length was set at 90 days as information on the dosage regimen was not available. The choice of the 90-day prescription length was based on the maximum allowed duration of an antidepressant prescription issued by GPs in the Netherlands. 12, 15 Patients were considered to have discontinued therapy if 30 days or more elapsed between the theoretical end date of an SSRI prescription and the subsequent SSRI prescription. In the original cohort, the study was designed in such a way that both SSRI and TCA were exposure variables; however, in the current study, the exposure of interest was only SSRI. Baseline TCA use, apart from inclusion of patients into the cohort, was considered as confounding variable and was adjusted for in each analysis.
Exposure to SSRI was further divided into episodes of current, recent, and past uses. Current use was considered as the calculated treatment episode plus 30 days after the estimated theoretical end date of the last prescription, to account for carry-over effects. Recent use included the period between 1 and 60 days after the period of current use. Past use included the period following recent use until a new SSRI prescription was filled or until the end of follow-up. In the cohort for this study, episodes of recent and past uses were considered a reference group, "no SSRI use," and episodes of current SSRI use were considered as "SSRI use." Each patient was followed from the first prescription until the occurrence of the first hip fracture or loss to follow-up (because of unregistration with the GP or death) or until the end of data collection (31 December 2009), whichever date came first. Hip fractures were identified by ICPC-2 codes and specific string texts in BIFAP and by ICPC-2 codes in Mondriaan. 12 Hip fractures were manually reviewed in BIFAP but not in Mondriaan. In the time-varying analysis, exposures only in the current and previous periods were considered relevant.
Potential confounders (co-medications and co-morbidities including baseline TCA use) were measured at baseline and updated whenever patients switched between exposure episodes (Table 1 footnote). When a patient was in the same exposure episode (current or past use), confounding factors were updated every 6 months (i.e., 182 days). The status of co-medication use as a confounding variable for the current period was defined as the use in the prior 182 days. Only chronic diseases such as diabetes mellitus and chronic obstructive pulmonary disease were considered as co-morbidities. If a patient is diagnosed with chronic condition (e.g., diabetes mellitus), he or she is considered as having the comorbidity from the first date of diagnosis for the rest of the time to the end of the study period. More details on study design, exposure, confounding, and outcome are available online at the ENCePP e-register of studies. 16 
Statistical analysis
First, time-fixed analysis accounting only for baseline covariates was conducted using conventional Cox proportional hazard models to give a benchmark for the degree of confounding by baseline variables included in the model. This analysis is based on the key assumption of the Cox model: the issue of non-informative censoring, meaning the mechanisms giving rise to censoring of individual subjects during follow-up are not related to the probability of an event, hip fracture, occurring. The estimates from adjusted models are "ever" versus "never" use ("intention-to-treat analysis") of SSRI during follow-up conditional on baseline covariates included in the models.
Next, three methods were applied to estimate the risk of hip fracture associated with the use of SSRI: (i) timevarying Cox regression models; (ii) PS methods; and (iii) MSMs. Time-varying Cox models were applied with and without adjustment for the demographic and clinical variables listed in Table 1 . Two PS techniques were applied: covariate adjustment using the PS (i.e., including the PS as independent variable in the regression model) and PS stratification. The PS was estimated using ordinary logistic regression including the demographic and clinical variables listed in Table 1 . The PS was defined as the probability of exposure to SSRI in a specific period, conditional on measured covariates in the previous period. The periods were based on exposure episodes as described earlier.
Hence, for each patient, the PS could change over time (i.e., it was considered time varying). We considered a PS model in which all measured covariates were included as main terms without any interaction or higher order terms. PS stratification was based on quintiles as well as deciles of the PS. The interaction between SSRI use and PS strata was tested in order to compare differences in treatment effect between strata. All PS methods used a Cox model as the model for treatment effect estimation. These analyses assume that censoring is non-informative within each period. The estimates from time-varying Cox and PS models are the net (total) effect of SSRI use (defined as SSRI use during the current and previous periods) on hip fracture conditional on the time-varying covariates and PS in the absence of informative censoring at each time point during follow-up. However, this net (total) effect of SSRI does not include the effect of SSRI use in the previous period that is mediated through subsequent timevarying covariates included in the Cox or PS model. This effect is "adjusted away" by conditioning on time-varying covariates or PS.
Propensity scores were also used to construct IPTW for the MSM. In the IPTW approach, the estimated PS was used to assign weights to all observations resulting in an altered composition of the study population, also referred to as a "pseudo-population." The weight for each patient was the inverse of the probability that the patient had the treatment that she or he actually received given a set of time-fixed and time-dependent covariates as well as previous treatment. Hence, the weights for SSRI users and non-SSRI users were 1/PS and 1/(1-PS), respectively. Then, cumulative weights were calculated for each patient by multiplying the weights up to that observation period. Finally, a Cox model was fitted using SSRI use as the only covariate in the pseudo-population created using the cumulative weights. To assess the possible impact of informative censoring, MSM with and without censoring weights, which are also cumulative over observation periods, was applied. In addition, stabilized weights were estimated by replacing the numerator of IPTW by the probability of SSRI use conditional on previous SSRI use or previous SSRI use, age, and gender. Stabilized treatment weights (STW i ) and censoring weights (SCW i ) were calculated using the method described by Hernan et al. 7 For detail on constructing the inverse probability of treatment and censoring weights, we refer to the Supporting Information (Appendix 2). The estimates from MSMs are the net (total) effect of SSRI use (defined as SSRI use during the current and previous periods) on hip fracture including the effect of SSRI mediated through subsequent time-varying covariates included in denominator of the weights. The estimates from MSMs are often marginal but can also be conditional (when age and gender are included in the outcome model), depending on the adjustment set, yet they are still marginal across other covariates. MSMs with censoring weights account for informative censoring related to covariate sets included in the denominator of the weights. Additional analyses adjusting for baseline TCA use, benzodiazepine use, and other covariates were also conducted. In MSMs, 95% confidence intervals were estimated using bootstrapping (number of bootstraps = 10 000). Furthermore, analysis using truncated (treatment and censoring) weights at 0.5th and 99.5th percentiles was performed. All analyses were performed in R, version 2.15.2, and correlation between observations was taken into account in both PS and Cox analyses using the cluster function in R. 17 In all analyses, we assumed exchangeability. The intervention is well defined; that is, there are no unrepresented versions of treatment, positivity, correct model specification, and no measurement error of exposures, covariates, or outcomes. For further details on these assumptions, we refer to the literature. Table 1 ). The mean ages were 49.4 years (±16.27) in Mondriaan and 52.6 years (±17.0) in BIFAP. The proportion of patients using SSRIs was 65.5% in the Mondriaan and 84.8% in the BIFAP cohort. The baseline characteristics of the two cohorts are shown in Table 1 . . Again, the estimates from adjusted models are conditional on the covariates included in the models (Table 3) . not account for censoring because it was only minimally informative given the results in Tables 5 and 6 . Table 5 When stabilized weights were trimmed at 0.5th and 99.5th percentiles, the treatment effect estimates in Mondriaan changed, particularly when adjustment was made for age and gender. On the other hand, weight truncation in BIFAP resulted in improved precision of the effect estimate without a substantial change in the point estimates even after adjustment was made for additional confounders ( Table 6 ). The range of the weights after truncation was narrower: 0 to 80 in Mondriaan and 0.33 to 1.65 in BIFAP. When weights were trimmed at 2.5th and 97.5th percentiles or at 1st and 99th percentiles, results were similar in both Mondriaan and BIFAP.
DISCUSSION
Our study shows that use of selective serotonin receptor inhibitor (SSRI) is associated with an increased risk of hip fracture in both cohorts (Mondriaan and BIFAP) when comparing with no SSRI use. In addition, this increased risk was consistently found for different analytical approaches: time-varying Cox model, PS methods, and MSMs. However, the magnitude of the association clearly differed between Mondriaan and BIFAP. For example, HR was 2.61 versus 1.52 using a time-varying Cox model and 2.13 versus 1.58 when applying MSMs in Mondriaan and BIFAP, respectively.
In both Mondriaan and BIFAP, estimates from timevarying Cox, time-varying PS models, and MSMs with and without accounting for censoring were similar. Differences in treatment effect estimates between the two cohorts are unlikely because of the applied methods for two reasons. First, the performance of the different methods to control for confounding was very similar within the two cohorts, but the impact of confounding adjustment was in opposite directions in the two cohorts. Second, substantial effort has been made to harmonize the design of the study, protocol, and data specifications. 14, 16 Possible explanations for the observed differences in confounding adjustment across databases may Both treatment and censoring weights were stabilized. BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; HR, hazard ratio. *Only inverse probability of treatment weights was used. † Combined inverse probability of treatment and censoring weights was used. include substantial differences in time-dependent confounding (particularly age) 8, 9, 12 and/or colliderstratification bias, 8, 9, 12, 20 non-collapsibility of the HR, 12, 21, 22 differences in quality of confounder information between the datasets, or the small number of events in Mondriaan leading to unstable estimates. With regard to the first possible explanation, timevarying Cox model and PS models condition on time-dependent covariates, for example, severity of depression, which may also be intermediates in the causal pathway between treatment (SSRI use at time t-1) and hip fracture, whereas MSMs reweight the original population without conditioning on such time-dependent covariates. When such timedependent confounders are affected by unmeasured factors that predict hip fracture risk (e.g., alcohol consumption, on which we had no information in Mondriaan), the analytic approaches considered, except MSMs, may induce collider-stratification bias. Although collider-stratification bias tends to be a less substantial source of bias than confounding, 21 under certain circumstances, it could result in a dramatic change not only in the magnitude of the effect estimate but also in the direction of the effect. 22, 23 In addition, similarity of effect estimate between conventional time-varying Cox regression, time-varying PS, and MSMs should be interpreted with caution. It might be possible that confounding due to adjustingaway the effect of previous treatment (by conditioning on the intermediate, time-dependent confounding) and collider-stratification bias might have similar magnitude but opposite direction, hence canceling out and leading to similar effect estimate to those of conventional methods. Regarding the second explanation, the magnitude of non-collapsibility increases with the effect of the covariate on the outcome, the baseline risk, and the strength of the treatment effect (the latter seems more likely in Mondriaan than BIFAP because non-collapsibility causes the estimate to change away from the null effect, HR = 1.0). 22, 24 However, non-collapsibility often results in an effect estimate away from the null, 21, 22 and its impact in practice is often difficult to quantify. In contrast, marginal estimates tend to be closer to the null effect than conditional estimates. 25 Thus, in our study, one would expect the PS estimates to be closer to an HR = 1 than the conventional estimates. However, this was not the case in our study (PS: HR = 2.82 and conventional: HR = 2.62), which implies that reasons other than noncollapsibility explain the differences, for example, misspecification of the outcome model for conventional models or inadequate balance due to misspecification of the PS model. Both time-dependent confounding and collider-stratification bias but not non-collapsibility can be best identified using causal diagrams. 20, 26 Inverse probability-weighted estimation of MSMs not only controls for time-dependent confounding without any risk of collider-stratification bias but also can account for bias because of informative censoring and be modified to accommodate competing risks. 8, 9 However, the impact of informative censoring seems minimal, if any, in both cohorts (assuming that the models for censoring are correctly specified and all predictors of informative censoring were observed). This was demonstrated by comparable treatment effect estimates with and without the use of censoring weights.
Weight truncation reduced variability of the weights and improved the precision, which has been described before. 27 However, treatment effect estimates were sensitive to weight truncation, particularly in Mondriaan, which could in part be due to strong covariate-treatment association and/or the small number of events in Mondriaan. Although the optimal level of truncation is difficult to determine, it is important to explore the sensitivity of effect estimates and precision to progressive weight truncations. Alternatively, other approaches proposed to deal with the positivity assumption could be employed. 28 Importantly, investigators should focus on the procedures leading to the generation of weights (i.e., proper specification of the PS model) rather than relying on ad hoc methods such as weight truncations. 27 We conducted this study in two large cohorts with a reasonably long follow-up time. In addition, detailed information was collected on exposure, co-morbidities, co-medications, and the outcome (hip fracture). However, the level of detail on important information such as co-morbidities limited optimal adjustment and comparison. 14, 16, 19 Although, there might still be unmeasured confounding because of patient characteristics not recorded in both databases, such as body mass index and alcohol consumption, we previously demonstrated that additional adjustment for these variables had limited impact on effect estimates. 19 In conclusion, this study indicates an increased risk of hip fracture associated with SSRI, which was consistently observed using different analytical approaches in two large electronic record healthcare databases. Although differences between methods to control for time-dependent confounding were small, relevant differences in treatment effect estimates between the two datasets were observed. These are possibly attributable to different confounder structures in the datasets, particularly of age.
